CVS HealthBSP:CVSH34 68 EBITDA Margin % is 5.80% as of Mar. 2026, which is 5% above its 10-year median of 5.55. GuruFocus rates BSP:CVSH34 with a GF Score™ of 68/100 and a GF Value™ of R$40.19 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 18 Healthcare Plans companies, CVS Health ranks worse than 61.11% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CVS Health's EBITDA for the
three
months ended in Mar. 2026 was R$30,473 Mil. CVS Health's Revenue for the
three
months ended in Mar. 2026 was R$525,188 Mil. Therefore, CVS Health's EBITDA margin for the quarter that ended in Mar. 2026 was 5.80%.
CVS Health (BSP:CVSH34) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CVS Health EBITDA Margin % Related Terms
CVS Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CVS Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:CVSH34 vs ELV, CI, HUM: EBITDA Margin % Comparison
For the Healthcare Plans subindustry, CVS Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CVS Health EBITDA Margin % vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, CVS Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CVS Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVS Health (BSP:CVSH34) has a EBITDA Margin % of 5.80% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CVS Health and its competitors. This is near median its historical median of 5.55. Over the past decade, CVS Health's EBITDA Margin % has ranged from 2.45 to 6.87. According to the industry distribution chart, CVS Health ranks #11 out of 18 companies in the Healthcare Plans industry, placing it in the top 61.1%.
Is CVS Health's EBITDA Margin % too high?
CVS Health's current EBITDA Margin % of 5.80% is near median its 10-year median of 5.55. Over the past 10 years, this metric has ranged from a low of 2.45 to a high of 6.87. The Healthcare Plans industry median EBITDA Margin % is 4.56. CVS Health's value of 5.80% is 27.3% above this industry median. Based on the distribution chart, CVS Health ranks #11 out of 18 companies in the Healthcare Plans industry, which is below the industry midpoint. Overall, CVS Health has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CVS Health's EBITDA Margin % compare to ELV and CI?
According to the Healthcare Plans industry distribution chart, CVS Health ranks #11 out of 18 companies for EBITDA Margin %. This places CVS Health in the lower half of its industry. The industry median EBITDA Margin % is 4.56. CVS Health's value of 5.80% is 27.3% above this benchmark. Historically, CVS Health's own EBITDA Margin % has ranged from 2.45 to 6.87 over the past decade. While the company's 10-year median is 5.55 vs. the industry median of 4.56, CVS Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Plans company?
The median EBITDA Margin % among Healthcare Plans companies is 4.56, based on 18 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CVS Health's current EBITDA Margin % of 5.80% is 27.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CVS Health and its competitors. For the Healthcare Plans industry, the median EBITDA Margin % is 4.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CVS Health's current EBITDA Margin % is 5.80%, which is near median its own 10-year median of 5.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CVS Health stock overvalued right now?
Based on GuruFocus' analysis, CVS Health (BSP:CVSH34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$40.19, compared to a current price of R$52.70 — trading 31.1% above its estimated fair value. The current EBITDA Margin % is 5.80%, which is near median its 10-year median of 5.55 and 27.3% above the Healthcare Plans industry median of 4.56. CVS Health's overall GF Score™ is 68/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CVS Health (BSP:CVSH34), the current EBITDA Margin % is 5.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CVS Health (BSP:CVSH34) Overvalued in 2026?
Based on GuruFocus' analysis, CVS Health stock appears to be overvalued.
The current stock price of R$52.70 is trading 31.1% above its estimated GF Value™ of R$40.19.
GuruFocus considers CVS Health to be Significantly Overvalued.
Key valuation signals for BSP:CVSH34:
EBITDA Margin %: 5.80% (near median its 10-year median of 5.55)
GF Value™: R$40.19 vs. price of R$52.70 (31.1% above fair value)
Industry Position: 27.3% above the Healthcare Plans median (#11 of 18)
No single metric tells the full story. See the BSP:CVSH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
68GF Score
Get the complete analysis for BSP:CVSH34
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:CVSH34 has been successfully added to your 
